Charcot-Marie-Tooth (CMT) – Market Outlook, Forecast and Competitive Landscape report- 2019-2030


Posted May 18, 2021 by thelansis

Charcot-Marie-Tooth disease (CMT) is one of a group of disorders that cause damage to the peripheral nerves.

 
Indication Overview:

Charcot-Marie-Tooth disease (CMT) is one of a group of disorders that cause damage to the peripheral nerves - the nerves that transmit information and signals from the brain and spinal cord to and from the rest of the body, as well as sensory information such as touch back to the spinal cord and brain.

Etiology

CMT is caused by mutations in genes that support or produce proteins involved in the structure and function of either the peripheral nerve axon or the myelin sheath. More than 40 genes have been identified in CMT, with each gene linked to one or more types of the disease.

View Report: Charcot-Marie-Tooth (CMT) – Market Outlook, Forecast and Competitive Landscape report- 2019-2030

Classification:
There are different types of CMT disease such as
CMT1 (caused by abnormalities in the myelin sheath.),
CMT2 (abnormalities in the axon of the peripheral nerve cell),
CMT3, or Dejerine-Sottas disease is a particularly severe demyelinating neuropathy that begins in infancy. This rare disorder can be caused by mutations in multiple genes, including PMP22, MPZ, and EGR2, and can be inherited either dominantly or recessively.
CMT4 comprises several different subtypes of demyelinating and axonal and motor neuropathies that are inherited autosomal recessively.
CMTX1 (also called CMT X, Type 1) is the second most common form of CMT. This X-linked disease is caused by mutations in a gene that provides instructions for making the protein connexin-32.

Epidemiology

CMT is one of the most common inherited neurological disorders, affecting an estimated 126,000 individuals in the United States and 2.6 million people worldwide.

Geography Covered

* North America - United States and Canada
* EU5 - Germany, France, Italy, Spain, and the United Kingdom
* Other EU Countries- Sweden, Denmark, Austria, Finland, Belgium, Netherlands, Switzerland, Poland, Russia, Japan
* APAC - Singapore, China, India, New Zealand, Australia
* LATAM - Brazil, Mexico, Argentina
* Middle East (Israel, Saudi Arabia and the United Arab Emirates, Morocco, Egypt, Turkey, Algeria)
Current Clinical Practice and Treatment Algorithm
Country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs are being covered under this section of the study. Retrospective analysis and bench-marking of clinical study outcomes are being presented in terms of Pr-treatment & post-treatment clinical and demographic patient characteristics.

KOL Insights - KOLs across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)
- Data Inputs with sourcing
- Market Event and Product Event
- Country specific Forecast Model
- Market uptake and patient share uptake
- Attribute Analysis
- Analog Analysis
- Disease burden and pricing scenario
- Summary and Insights

Clinical Trial Assessment:

Detailed clinical trial data analysis and key product positioning includes trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events.

Unmet Medical Needs Overview:

This report presents the most important clinical unmet needs in the treatment, according to Thelansis’s primary market research and analysis. Other important unmet needs identified through our research, include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Contact Us

About Thelansis: - As the name depicts Thelansis is specialized in “Therapy Area Landscape Analy- sis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook and Market Access Reports. Our focused therapeutic approach provides our clients with clinical and disease area expertise from an integrated team of academic, medical, and industry specialists of our panel, Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at,
[email protected]
Peeyush Potdar

Delivery Head:
Email: [email protected]
Visit us at http://www.thelansis.com/

Delivery office
B-1030, C Wing
Vrindavan tech village Marathahalli
Outer ring road, Bangalore- 560037

Sales office
183-Asylum Street Hartfort, CT-06103, USA

Telephone
USA +1-302-380-3552, India +91-9899921259

Email
[email protected], [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Thelansis
Country India
Categories Health
Tags charcotmarietooth , charcotmarietooth cmt , charcotmarietooth cmt market outlook report , primary market research , thelansis
Last Updated May 18, 2021